proceed to the innovation in the pharmaceutical industry. the case of spain
Clicks: 180
ID: 202430
2015
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
3.3
/100
11 views
11 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
This article explores sectors identified innovation in Spanish pharmaceutical companies. It also considers domestic firms and foreign subsidiaries in the country. The analysis covers the period 2009 to 2011 for a population N=200 affiliates at that time Farmaindustria and Plan Profarma. The work involved a search of useful information on the websites of pharmaceutical companies based in Spain statically describes the innovative profile of the Spanish pharmaceutical through descriptive statistical analysis. Thus a foundation for documenting the results in a database in order to get a picture with determination on the behavior of Spanish pharmaceutical sector and possible trends is created.The high content of literary contribution on the pharmaceutical sector is expressed in a globalized national and international level, rejecting data and information that could provide signals threat or opportunity regarding short period time, and which in turn are comparable to other years since the Spanish pharmaceutical industry is constituted by companies of foreign origin (50.5%) and domestic capital (49.5%). Of the latter SMEs are the protagonists of small innovations established in Madrid and Barcelona mainly.
| Reference Key |
garca2015revistaproceed
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Aída Salazar García;Elicet Cruz Jiménez;Joaquim Lloveras Macia;Guillermo Manuel Urriolagoitia Calderón |
| Journal | gigascience |
| Year | 2015 |
| DOI |
10.15446/rev.colomb.biote.v17n1.50691
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.